Revance Therapeutics, Inc.Company Review & Valuation

RVNC
Nasdaq
Latest Price
25.74USD
Market Capitalization
1,467.96mUSD

About Revance Therapeutics, Inc.

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III Show moreclinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. Revance Therapeutics, Inc. has a collaboration agreement with Mylan N.V. (MYL) for the development, manufacture, and commercialization of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.Show less

Industry
Biotechnology
HQ Location
Newark, California

Stock Price

Price data not available for Revance Therapeutics, Inc..

Performance

Please login or create a free account to view the contents of this section.

Similar Companies

BioTime
Apricus Biosciences
Atara Biotherapeutics
Biogen

back to top